AK-IN-1, a competitive inhibitor for adenosine (Ado) but not for ATP, demonstrates significant inhibition of AK activity, achieving 86%, 87%, and 89% at concentrations of 2, 4, and 10 µM, respectively. This compound shows promise for research across various disease areas, such as ischemia, inflammation, and seizures.